Product Development

Immunomedics data point to Trodelvy’s $21B potential

Plus ESMO data from Amgen, J&J, AstraZeneca and BMS

New data from Immunomedics suggest its antibody-drug conjugate Trodelvy is on track for the label expansions worked into Gilead’s $21 billion takeout price for the biotech. At the European Society for Clinical Oncology Virtual Congress, the company shared a pair of posters that provide confirmatory data for Trodelvy in triple-negative breast cancer following its conditional approval in April, and make the case for